本计划的主要目标是在香港中文大学建立一个创新模式的全面精准肿瘤学平台，协助为晚期癌症患者制定个人化药物治疗。其他目标包括优化基因组配对，以及让具有独特癌症亚型的患者能参与相关的新疗法临床试验，并为个人构建个人化药物筛选平台。
适应症：Gastrointestinal Cancers
入组条件
纳入标准
- Must be aged between 18 to 75 years
- Must have ECOG performance status of 0 to 1
- Must have histologically/cytologically confirmed cancers of certain subtype
- Medically fit patients who would need systemic therapy as part of their oncological treatment in any one or more of the following oncological setting(s): palliative, neoadjuvant, adjuvant, concurrent with radiotherapy. This includes patients who have limited systemic therapeutic options for their cancers and are candidates for clinical trials.
- Able to give written informed consent
- Willing to have blood samples taken.
- Availability of an archived paraffin-embedded tumor block
排除标准
- Patients who refuse or are medically unfit for systemic therapy for their cancer
- Patients with more than one invasive cancers diagnosed over the last FIVE years.
- Patients without measurable tumor lesions on radiological imaging
- Patients who are unable to give written informed consent.
入组条件维持 ClinicalTrials.gov 原始英文登记资料，实际入组资格以研究团队的正式评估与受试者知情同意书为准。资料来源：ClinicalTrials.gov，每两周自动更新，最后同步：2026年10月8日。